Dozens of foreign CEOs will visit Beijing this month for a flagship business conference and some will meet with President Xi ...

U.S. FIRMS In addition to the CEOs of Qualcomm, FedEx, Standard Chartered, Citadel, Bain and KPMG, Pfizer CEO Albert Bourla, ...

Orforgliprone is Eli Lilly's second glucagon-like peptide-1 (GLP-1) based obesity drug, developed following the injectable obesity treatment Zepbound (marketed as Mounjaro in South Korea), and it ...

In addition, Eli Lilly announced earlier this month that it is paying $630m for South Korea-based biotech OliX Pharmaceuticals’ antisense RNAi oligonucleotide OLX75016 to treat MASH.

Eli Lilly has opted to end a phase 2 rheumatoid arthritis (RA) trial of a drug it is developing with Korea’s Hanmi Pharmaceuticals, according to press reports. The Korea Biomedical Review cited ...

The company entered into a global licensing deal with South Korea’s OliX Pharmaceuticals that could be valued at up to $630 million. As per the agreement, Eli Lilly and Company (NYSE:LLY ...

Vivozon Pharmaceutical, a South Korean company specializing in the development and distribution of pharmaceutical drugs, is ...

Eli Lilly is also conducting phase 2 trials for the amylin analog ... It felt like becoming Superman ... Korea plans Science Media Center to connect researchers with media The Ministry of Science and ...

In addition, Eli Lilly announced earlier this month that it is paying $630m for South Korea-based biotech OliX Pharmaceuticals’ antisense RNAi oligonucleotide OLX75016 to treat MASH. "Eli Lilly pays ...

Maxion Therapeutics Raises $72 million (£58 million) in an Oversubscribed Series A Financing to Advance its KnotBody® Pipeline and Platform Financing led by General Catalyst with additional investment ...

Lantheus Holdings, Inc.'s stock soars 55%, fueled by Pylarify and strategic acquisitions in Alzheimer's and oncology. Click ...